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more frequent in certain ethnic groups, e.g. 
African-Americans and Hispanics [2]. The 
broad spectrum of clinical presentations 
makes the SLE the prototypic multisystem 
IntroduCtIon
Systemic lupus erythematosus (SLE) is a 
heterogeneous autoimmune disorder char-
acterized by multisystemic involvement. 
Although the exact etiology has not been 
determined, it has been shown that genetic, 
environmental, and hormonal factors play a 
role in its pathogenesis. SLE is characterized 
by disturbances of both innate and adap-
tive immune systems, with dysregulation of 
T and B cells, cytokines secretion, and au-
toantibodies production [1]. Its prevalence 
ranges from 40 to 200 cases per 100,000 
[2]. Women are affected by SLE nine times 
more frequently than men, particularly af-
ter puberty and before menopause [2]. For 
reasons not entirely understood, SLE is also 
Why we describe this case
The occurrence of osteoporosis in SLE 
patients has been widely described in lit-
erature. However, often in SLE patients 
kidney dysfunction or kidney failure con-
cur, for which bisphosphonates are con-
traindicated. Therefore, it is mandatory 
to find osteoporosis treatments compat-
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Case report
Abstract
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by 
multisystemic involvement. Owing to multifactorial etiologies, low bone mineral density (BMD) 
osteoporosis (OP) and fragility fractures (FFx) have been very frequently documented in these 
patients. Appropriate treatments to minimize underlying immunologic disease activity remain 
mandatory, and the development of strategies to prevent and treat important complications as 
osteoporosis is needed.
We present the clinical case of a female SLE patient treated simultaneously with belimumab 
(anti-BLyS) for the underlying disease, and denosumab (anti-RANKL) for concomitant 
severe osteoporosis. As these monoclonal antibodies have been recently introduced into the 
market, their combination has not been reported in literature yet. In this case, the combined 
administration proved a viable option for a SLE patient with osteoporosis and bisphosphonates 
contraindications. 
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autoimmune disease. It may present with 
very different clinical manifestations, rang-
ing from fatigue and mild skin rash to end-
stage renal failure [2,3]. A wide spectrum 
of clinical and serological findings often 
misleads and delays the diagnosis. Therefore, 
SLE diagnosis still represents a challenge, 
remaining largely based on clinical judgment 
[3] and requiring often an interdisciplinary 
approach [4].
In 2012, the Systemic Lupus International 
Collaborating Clinics (SLICC) network 
presented a set of criteria (SLICC-12) to 
classify the disease [5]: in the validation set, 
the SLICC classification criteria resulted in 
fewer misclassifications compared with the 
revised 1997 American College of Rheu-
matology (ACR) classification criteria [6]; 
besides, it had a greater sensitivity (97% 
versus 83%) but a lower specificity (84% 
versus 96%) [5]. According to the SLICC 
criteria, the classification of SLE seems to 
be achieved more frequently than with the 
previous 1997 ACR criteria [3,7]. The clini-
cal course of SLE is characterized by spon-
taneous or treatment-induced remissions 
and flares. Steroids and immunosuppressive 
drugs are the cornerstone of SLE treatment, 
but their use, especially in high doses and for 
long periods, may be burdened by the onset 
of medication-induced adverse effects.
The occurrence of osteopenia, osteoporosis 
(OP), and fragility fractures (FFx) in SLE 
patients has been widely described in litera-
ture [8-13]. Osteopenia and osteoporosis are 
reported in 25-74% and in 1.4-68% of SLE 
patients, respectively, and the occurrence of 
symptomatic fractures is increased 5-fold in 
women with SLE [14]. These frequencies 
vary widely as a consequence of differences 
in size, age, sex, ethnicity, disease severity, 
and medication use between the patient 
groups investigated [14].
The etiology of bone loss in SLE is sup-
posed to be multifactorial, including tradi-
tional osteoporosis risk factors, inflamma-
tion, contraindications to sun exposure and 
subsequent reduction of activation of vita-
min D, metabolic factors, hormonal factors, 
serologic factors, and medication-induced 
adverse effects [12,14,15].
We report the case of a woman affected 
by SLE and severe osteoporosis with os-
teoporotic fractures, contraindication to 
bisphosphonates due to a history of renal 
insufficiency, and concomitantly treated 
with belimumab and denosumab, two re-
cently marketed monoclonal antibodies. 
Belimumab’s mechanism of action is based 
on the known pathological functions of B 
lymphocyte stimulator (BLyS), a tumor 
necrosis factor (TNF) superfamily ligand. 
BLyS plays a critical role in the development 
and homeostasis of B lymphocytes. Under 
pathological conditions (as occurs in SLE), 
B lymphocytes produce the auto-antibodies 
responsible for the clinical features of SLE. 
By inhibiting BLyS, belimumab is able to 
effectively block this pathological pathway 
[8,16,17]. Denosumab is an anti-receptor 
activator of nuclear factor-kappaB (NFκB) 
ligand antibody, a fully human monoclonal 
antibody that binds the cytokine RANKL 
(receptor activator of NFκB ligand), an 
essential factor initiating bone turnover. 
RANKL inhibition blocks osteoclast matu-
ration, function and survival, thus reducing 
bone resorption [18-20].
To date, there are no studies in literature 
on the efficacy and safety of combination 
therapy with belimumab and denosumab. 
This is probably due to the recent introduc-
tion on the market of these monoclonal 
antibodies.
CASE prESEntAtIon
We report the case of a 54-year-old female 
patient. In 2004, she came to our attention 
with malar rash, migratory arthralgias, recur-
rent epistaxis, and morning articular stiffness 
lasting more than one hour. Her previous 
medical history was significant for arterial 
hypertension, turbinate hypertrophy, and 
occasional leukopenia.
Laboratory analyses showed leukopenia, 
thrombocytopenia with antinuclear antibod-
ies (ANA) = 1/160 with granular pattern on 
immunofluorescence, anti-dsDNA positive, 
hypocomplementemia (Table I), presence of 
lupus anticoagulant antibodies and anti-
beta2-glycoprotein I IgG, and anticardio-
lipin IgG positive at low levels.
After a deep vein thrombosis with pulmo-
nary thromboembolism, the patient had to 
start warfarin therapy. Furthermore, a MRI 
of the encephalon, requested for the suspi-
cion of neurological involvement, showed 
signs of microischemic strokes.
According to the ACR 1997 criteria, a 
diagnosis of SLE was made, and the patient 
started a therapy with prednisone (initially 
at high dose, 25 mg/die) and hydroxychlo-
roquine (200 mg/die), while awaiting the 
therapy with cyclophosphamide, which was 
started in September 2004 and shortly af-
terwards suspended owing to pancytopenia 
and gastrointestinal intolerance.
Due to incomplete disease control with 
steroid and hydroxychloroquine therapy 
(hypocomplementemia, anemia, and ar-
thralgia were still present) she was given a 
therapy based on azathioprine, which was 
suspended, alongside hydroxychloroquine, 
because of the worsening of leukopenia (Au-
gust 2005). From 2005 to 2013, the disease 
went to partial remission with steroid only 
therapy (treatment range between 10 and 
12.5 mg/die).
In March 2013, during treatment with 
prednisone 12.5 mg/die, her renal function 
worsened: serum creatinine was 3.1 mg/dl 
and proteinuria increased to 0.9 g/24 hours. 
Even though lupus nephritis was suspected, 
renal biopsy was not performed because se-
rum creatinine and proteinuria decreased 
after starting ACE-inhibitors; however, 
bisphosphonates, that she had been taking 
parameter detected value normal values
WBC (n/l) 2800 4000-10,000
Neutrophils (n/l) 1800 1500-8000
Lymphocytes (n/l) 800 1000-4000
PLTs (n/l) 98,000 140,000-450,000
ANA 1/160 < 1/80
Anti-dsDNA (UI/l) 89 < 10
C3 (mg/dl) 25 83
C4 (mg/dl) 8 15
table I. Laboratory 
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since 2011 for a high risk of bone fracture 
documented by a dual-energy X-ray absorpti-
ometry (DXA) with a vertebral T-score -3.0, 
were suspended. As osteoporosis-prophylaxis, 
the patient continued therapy with calcium 
carbonate and vitamin D (calcifediol).
Alongside ACE-inhibitor treatment, she 
started therapy with mycophenolate (500 mg 
twice a day) and her serum creatinine stabi-
lized, reaching mean values = 1.2-1.4 mg/dl, 
denoting stage 2 renal insufficiency accord-
ing to Kidney Disease Outcomes Quality 
Initiative (NKF KDOQI)™ classification.
In February 2014, mycophenolate was 
suspended for gastrointestinal intolerance 
and a mild non erosive poliarthritis; her re-
nal situation was stable, with no proteinuria.
She presented in March 2014 with anti-
dsDNA persistently positive (Table II), low 
complement levels, persistent fatigue, and 
oligoarthritis on wrists and small joints of 
the hand.
After proper literature searches and dis-
cussion with nephrologists, she was given 
a therapy with belimumab (Benlysta®) at 
the dosage of 10 mg/kg (600 mg) once ev-
ery month.
After six infusions, in August 2014 the 
patient had a good clinical and serological 
response: no drug adverse event arose during 
treatment, arthritis reached clinical remis-
sion, renal function (creatininemia and pro-
teinuria) remained satisfactory, and no flares 
of SLE had happened. Complement levels 
improved (Table II), anti-dsDNA reduced, 
no hematological alterations occurred, and 
total dosage of prednisone could be reduced 
to 7.5 mg/die.
March 
2014 – first 
administration of 
belimumab
August 2014 – 
after 5 months 
of therapy with 
belimumab
december 
2014 – first 
administration of 
denosumab






SLEDAI 13 10 - 6 6
WBC (n/l) 3340 3216 3412 3945 6440
HB (g/dl) 10.9 11.1 11 11.4 10.4
PLTs (n/l) 130,000 126,000 146,000 126,000 254,000
Creatinine (mg/dl) 1.89 1.95 2.01 2.05 1.71
Proteinuria no no no no no
C3 (mg/dl) 32 79 82 68 85
C4 (mg/dl) 11 18 21 17 12
Arthritis yes no no no no
ANA 1/640 1/320 1/320 1/640 1/320
Anti-dsDNA (UI/l) 72 22 40 64 38
table II. Laboratory 
analyses performed 










Activity Index;  
WBC = White Blood Cells
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start warfarin therapy. Furthermore, a MRI 
of the encephalon, requested for the suspi-
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started in September 2004 and shortly af-
terwards suspended owing to pancytopenia 
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tion, metabolic factors, and medication-in-
duced adverse effects. Osteoporotic fractures 
are present in 20-26.1% of SLE patients and 
often an appropriate treatment is mandatory. 
At the same time, a large number of SLE 
patients suffer from many comorbidities 
and many organ involvement by the un-
derlying disease [2,3,11,12,14]: therefore, 
they need a basic therapy able to ensure an 
absent or a low SLE disease activity, and at 
the same time an appropriate therapy for 
the osteopenia/osteoporosis. Nowadays, an 
increasing number of patients are treated 
with belimumab, due to its proven efficacy 
in reducing flares. As a result, case reports 
and trials concerning this association and its 
interactions are required.
In this case report, the treatment with 
belimumab and denosumab resulted in im-
proved patient’s conditions. By considering 
the mechanisms of action of the two drugs 
(anti-RANKL and anti-BLyS), we do be-
lieve that the combined administration could 
be a viable option for patients with SLE, 
osteoporosis, and bisphosphonates contrain-
dications. Finally, the six-month administra-
tion of denosumab is particularly suitable for 
patients who are exhausted because of their 
multiple chronic therapies; furthermore, 
it ensures an effective alternative therapy, 
since no side effects concerning kidneys (as 
opposed to bisphosphonates) and hearth 
(a known side effect of strontium ranelate) 
were detected.
Key points
 y Etiology of bone loss in systemic lupus erythematosus (SLE) is multifactorial, including 
traditional osteoporosis risk factors, inflammation, metabolic factors, and medication in-
duced adverse effects
 y In SLE patients, often kidney dysfunction or kidney failure concur, thereby contraindicat-
ing the use of bisphosphonates
 y Considering the mechanisms of action of belimumab (anti-BLyS) and denosumab (anti-
RANKL), two monoclonal antibodies acting upon two different molecular pathways, 
combined administration could be a worth option to be considered for patients with SLE, 
renal insufficiency, and osteoporosis
In December 2014, the patient had a 
spontaneous rib fracture and right metatar-
sal heads stress fractures. Dual-energy X-ray 
absorptiometry (DXA) showed reduced bone 
mineral density with vertebral T-Score = -3.2. 
At that time, her osteoporosis was treated 
with calcifediol 50.000/UI per month and 
calcium carbonate every day. Bisphospho-
nates were suspended due to contraindica-
tions for renal insufficiency. Given this clini-
cal picture, the patient started denosumab 
(Prolia®) 60 mg administered as a single sub-
cutaneous injection once every 6 months, in 
association with calcium 1000 mg daily and 
supplementation of already set vitamin D.
In February 2016, DXA documented a 
vertebral T-score = -1.7. No new spontane-
ous fractures occurred. The patient continued 
the treatment with belimumab 10 mg/kg/
month and denosumab 60 mg/6 month, and 
we could reduce the dosage of prednisone to 
5 mg/die. To date, she has had thirty-two 
infusions of belimumab and five injections 
of denosumab.
dISCuSSIon And ConCLuSIon
In literature, there are no case reports 
about the concurrent use of two monoclonal 
antibodies as belimumab and denosumab.
The etiology of bone loss in SLE is sup-
posed to be multifactorial, including tradi-
tional osteoporosis risk factors, inflamma-
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